ALUNBRIG

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug ALUNBRIG contains one active pharmaceutical ingredient (API):

1	Brigatinib UNII HYW8DB273J - BRIGATINIB
	Brigatinib is a tyrosine kinase inhibitor that targets ALK, c-ros oncogene 1 (ROS1), and insulin-like growth factor 1 receptor (IGF-1R). It is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
	Read more about Brigatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ALUNBRIG Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
ALUNBRIG Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01ED04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01ED Anaplastic lymphoma kinase (ALK) inhibitors
Discover more medicines within L01ED04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11974F, 11976H, 11980M, 11984R
CA	Health Products and Food Branch	02479206, 02479214, 02479222, 02479230
EE	Ravimiamet	1763490, 1781883, 1783201, 1783212, 1783223, 1783234, 1783245, 1783256, 1783267, 1783289, 1783290, 1806870
ES	Centro de información online de medicamentos de la AEMPS	1181264008, 1181264010, 1181264011, 1181264012
FI	Lääkealan turvallisuus- ja kehittämiskeskus	070285, 090597, 165823, 197613, 426670, 428410
FR	Base de données publique des médicaments	60648770, 61066196, 62626993, 66949061
GB	Medicines & Healthcare Products Regulatory Agency	365898, 365918, 367938, 378508, 378509
HK	Department of Health Drug Office	66119, 66120, 66121
IE	Health Products Regulatory Authority	88987, 88988, 88995, 88996
IL	מִשְׂרַד הַבְּרִיאוּת	8108, 8110
JP	医薬品医療機器総合機構	4291069F1022, 4291069F2029
LT	Valstybinė vaistų kontrolės tarnyba	1086610, 1086611, 1086612, 1086613, 1086614, 1086615, 1086616, 1086617, 1086618, 1086619, 1087058, 1087059
NL	Z-Index G-Standaard	16753798
NL	Z-Index G-Standaard, PRK	196045, 196053, 196061, 197238
PL	Rejestru Produktów Leczniczych	100416370, 100416387, 100416393, 100416980
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65342001, W65342002, W65343001, W65343002, W65344001, W66552001
SG	Health Sciences Authority	15658P, 15659P, 15660P, 15661P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699456090110, 8699456090127, 8699456090134, 8699456090141, 8699456090158, 8699456090165, 8699456090172, 8699456090189, 8699456090219
US	FDA, National Drug Code	63020-090, 63020-113, 63020-180, 76189-113